A5078747161- Inflammatory Bowel Disease
- Microscopic Colitis
- Liver Diseases and Immunity
- Celiac Disease Research and Management
- Eosinophilic Esophagitis
- Chronic Lymphocytic Leukemia Research
- Mycobacterium research and diagnosis
- Biosimilars and Bioanalytical Methods
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Diagnosis and treatment of tuberculosis
- Health Systems, Economic Evaluations, Quality of Life
- Tuberculosis Research and Epidemiology
- Helicobacter pylori-related gastroenterology studies
- Antifungal resistance and susceptibility
- Pregnancy and Medication Impact
- Congenital Anomalies and Fetal Surgery
- Aortic aneurysm repair treatments
- Fungal Infections and Studies
- Calcium signaling and nucleotide metabolism
- Autoimmune and Inflammatory Disorders Research
- Viral gastroenteritis research and epidemiology
- Acute Lymphoblastic Leukemia research
- Colorectal Cancer Treatments and Studies
- Delphi Technique in Research
Concord Repatriation General Hospital
2019-2025
The University of Sydney
2017-2025
Australian National University
2025
National University College
2025
New Generation University College
2025
Concord Hospital
2025
Services Australia
2022
UNSW Sydney
2017
St Vincent's Hospital Sydney
2014-2016
Royal Prince Alfred Hospital
2016
The expanding options in advanced therapies for ulcerative colitis (UC) and Crohn's disease (CD) present challenges treatment selection. Persistence analysis assesses drug durability real-world settings, acting as a surrogate marker medication efficacy tolerance. Unlike traditional comparative studies, persistence provides insights extending beyond the initial year of treatment.
Abstract Background The optimal dosing strategy of infliximab (IFX) in Acute Severe Ulcerative Colitis (ASUC) is unknown. We compared intensified and standard dose IFX strategies ASUC. Methods In this open-label randomised trial (NCT02770040), patients from 13 Australian centres with intravenous steroid-refractory ASUC were to receive a first 10mg/kg or 5mg/kg 1:2 ratio. Patients the group (intensified induction [II]) received second at day 7 earlier time non-response; all re-randomised 1:1...
The impact of thiopurine de-escalation while on vedolizumab versus continuing therapy in ulcerative colitis (UC) is unclear. We aimed to determine the effect withdrawal for patients with UC remission vedolizumab.
The choice between infliximab (IFX) and vedolizumab (VED) as a first-line biological agent in moderate-to-severe ulcerative colitis (UC) can be difficult. Second-line efficacy may decline following prior treatment failure UC patients. However, it is not known whether second-line IFX declines after of VED.We aimed to compare persistence VED, particular VED.Persistence VED was analysed from the Australian Pharmaceutical Benefits Scheme registry data either first- or UC. Propensity score...
Abstract Background Disease clearance (DC), defined as combined clinical, endoscopic and histologic remission, has been proposed the ultimate therapeutic target in ulcerative colitis (UC). However, addition of faecal calprotectin (FC) remission to DC, now ‘extensive disease (EDC)’, predicting for relapse is unknown. We aimed explore use composite endpoints, including DC EDC, long-term outcomes UC patients on vedolizumab (VED). Methods The phase IV Vedolizumab Immunomodulator Enforced...
Abstract Background The ability to predict failure of infliximab (IFX) in acute severe ulcerative colitis (ASUC) is crucial identify patients who may benefit from dose-escalation, sequential rescue or early colectomy. Methods PREDICT-UC (NCT02770040) was a randomised controlled trial that compared IFX dosing strategies ASUC.1 Clinical factors and biomarkers were collected daily between day 0 3 post-IFX assessed on their (Lichtiger score ≥10 14) 3-month Stepwise logistic regression used...
Abstract Background Faecal calprotectin (FCP) is routinely used in the management of inflammatory bowel disease; however, its role acute severe ulcerative colitis (ASUC) unclear. We aimed to evaluate relationship between FCP and outcomes ASUC. Methods included ASUC patients who were screened/randomised as part PREDICT-UC (NCT02770040), a randomised controlled trial that evaluated escalated infliximab (IFX) dosing strategies steroid-refractory ASUC.1 Stool was collected at screening, day 0...
Abstract Background Biochemical, endoscopic and histologic endpoints are commonly used to objectively define remission status in ulcerative colitis (UC). Little data exists on the correlation of these from prospectively collected samples based a well-defined protocol. Also, optimal faecal calprotectin (FC) values that predict histo-endoscopic lacking. Methods The phase IV Vedolizumab Immunomodulator Enforced Withdrawal Study (VIEWS) recruited 62 patients with UC vedolizumab steroid-free...
Abstract Background Mucosal histological activity is increasingly valued as a treatment endpoint in inflammatory bowel diseases (IBD). In the Asia Pacific region, however, utility and acceptability of IBD histology uncertain due to heterogeneity prevalence, resourcing, level knowledge among practitioners. There an opportunity engage clinicians harmonise reporting collaborate with pathologists this field. To end, we developed statements determine their consensus through anonymous voting on...
Abstract Background The utility of infliximab (IFX) therapeutic drug monitoring (TDM) in acute severe ulcerative colitis (ASUC) is unclear. We aimed to assess whether IFX levels are associated with outcomes ASUC. Methods PREDICT-UC (NCT02770040) was a randomised controlled trial that compared dosing strategies 138 steroid-refractory ASUC patients.1 Serum and faecal were quantified by ELISA (MabTrack level infliximab, Essange Reagents, Netherlands) after conclusion the correlated outcomes:...
The epithelial barrier's primary role is to protect against entry of foreign and pathogenic elements. Both COVID-19 Inflammatory Bowel Disease (IBD) show commonalities in symptoms treatment with sensitization the barrier inviting an immune response. In this study we use a multi-omics strategy identify common signature disease that may be able predict for more severe patient outcomes. Global proteomic approaches were applied transcriptome proteome. Further semi- relative- quantitative...
INTRODUCTION: Comparative effectiveness research provides data on the relative benefits and risks between treatments. In Crohn's disease (CD), however, there are few head-to-head studies comparing advanced therapies none with long-term follow-up. Real-world effectiveness, defined by treatment persistence, obtained from prospective population-based patient cohorts, may help determine best sequencing positioning of biological agents. METHODS: We analyzed prospectively collected Australian...
Objectives To determine the age-standardised prevalence of inflammatory bowel disease (IBD) in a metropolitan area Sydney, with focus on its among older people. Design, setting Population-based epidemiological study people IBD City Canada Bay, local government inner west during 1 March 2016 – 10 November 2016. Participants Patients diagnosed confirmed according to Copenhagen or revised Porto criteria. Main outcome measures Crude IBD, including Crohn and ulcerative colitis; based World Health...
Background and aims: Comorbidities, polypharmacy, malignancies, infections complicate management of elderly patients with inflammatory bowel diseases (IBD). This study assessed gastroenterologists’ preference in the prescription medications or surgery to IBD, factors associated their choices. Methods An international case-based survey was conducted that presented three cases steroid-dependent ulcerative colitis assessing young-age versus elderly-age patients, without comorbidity. Physician...
Crohn's Disease (CD) is a relapsing inflammation of the gastrointestinal tract that affects young working age population and increasing in developing countries. Half all sufferers will experience stricturing or fistulizing intestinal complications require extensive surgical interventions neither genes nor clinical risk factors can predict this debilitating natural history. We applied discovery verification phase studies as part an NCI-FDA modeled biomarker pipeline to identify differences...
Histological remission is increasingly accepted as a treatment endpoint in the management of ulcerative colitis (UC). However, knowledge histology guidelines and attitudes towards their use clinical practice by gastroenterologists pathologists unknown.To evaluate UC pathologists.A prospective, cross-sectional nationwide survey who analyse specimens was conducted. The consisted 34 questions to assess gastroenterologists' pathologists' (score out 19) histological assessment UC. Survey were...
Cryptococcus neoformans is an opportunistic fungal pathogen and important cause of morbidity mortality in immunocompromised patients. We report a case osteomyelitis caused by C. liver transplant recipient who presented with headache scalp lump after sustaining mild head trauma. There was no evidence central nervous system involvement or dissemination. This the first known isolated cryptococcal recipient.
'Dose tailoring' of anti-tumour necrosis factor alpha (TNF-α) therapy in Crohn disease (CD), by dose escalation, or shortening dosing intervals, has been suggested to regain clinical response following a flare proportion patients. However, reported outcome data are sparse and none exists from Australia.In an observational multicentre, retrospective study, the impact anti-TNF-α tailoring on corticosteroid use, need for surgery physician perception efficacy was examined real-world setting at...
Abstract Background The benefit of continuing thiopurine in ulcerative colitis (UC) responders to vedolizumab (VED) is unclear. We aimed determine the effect withdrawal VED-treated UC patients on combination therapy. Methods This prospective multi-centre, single-blind, randomised controlled trial recruited VED 300mg IV every 8 weeks and a for ≥6 months. Patients steroid-free clinical remission (partial Mayo score[pMS]≤2, no subscore>1) endoscopic remission/improvement (Mayo...
Abstract Background The efficacy of infliximab has been demonstrated in patients with both acute severe and moderate‐severe ulcerative colitis ( UC ). However, there is a need for ‘real‐life data’ to ensure that conclusions from trial settings are applicable usual care. We therefore examined the national experience anti‐tumour necrosis factor‐α TNF ‐α) therapy . Methods Case notes review who had received compassionate access CA ) anti‐ ‐α prospectively maintained inflammatory bowel disease...